This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / H. Lundbeck receives South Korea...
Business marketing authorization

H. Lundbeck receives South Korea migraine drug approval

Analysis based on 7 articles · First reported May 26, 2026 · Last updated May 26, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The marketing authorization for eptinezumab in South Korea is expected to positively impact Lundbeck's stock price due to expanded market access and potential revenue growth. It also provides a new treatment option for migraine patients in South Korea, potentially affecting the healthcare market in the region.

Pharmaceuticals Healthcare
Event Summary

Lundbeck announced that the South Korea — Ministry of Food and Drug Safety of South Korea has granted marketing authorization for eptinezumab (Vyepti) for the preventive treatment of migraine in adults. This approval is a significant milestone for Lundbeck, expanding its global reach for the intravenous migraine treatment, which has already been approved by the United States — Food and Drug Administration and the International — European Commission and launched in over 30 markets worldwide. The decision is supported by results from several Phase 3 trials, including the SUNRISE trial conducted in a predominantly Asian population. This new treatment option addresses a significant unmet need for the approximately 11% of the South Korea population living with migraine.

Entities Involved
priv
Lundbeck
Lundbeck received marketing authorization for its migraine treatment, eptinezumab, in South Korea, expanding its global market presence and potential revenue.
Importance 100.0 Sentiment 70.0
govactor
South Korea — Ministry of Food and Drug Safety
The South Korea — Ministry of Food and Drug Safety granted the marketing authorization for eptinezumab in South Korea.
Importance 80.0 Sentiment 0.0
cnt
South Korea
South Korea's South Korea — Ministry of Food and Drug Safety granted marketing authorization, providing a new treatment option for its citizens suffering from migraine.
Importance 80.0 Sentiment 0.0
per
Johan Luthman
Johan Luthman, EVP and Head of Research and Development at Lundbeck, commented on the significance of the approval for migraine patients in South Korea.
Importance 30.0 Sentiment 0.0
govactor
International — European Commission
The International — European Commission previously granted marketing authorization for eptinezumab for migraine prophylaxis in adults.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration previously approved eptinezumab for preventive migraine treatment in adults.
Importance 20.0 Sentiment 0.0
alliance
European Union
Eptinezumab received prior approval in the European Union.
Importance 10.0 Sentiment 0.0
Relationships
South Korea related ↔ International — European Commission
South Korea related ↔ European Union
International — European Commission related ↔ United States — Food and Drug Administration
International — European Commission related ↔ European Union
United States — Food and Drug Administration related ↔ European Union
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.